↓ Skip to main content

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Overview of attention for article published in Alzheimer's Research & Therapy, April 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#33 of 1,465)
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news
23 news outlets
twitter
3 X users
patent
2 patents
facebook
2 Facebook pages

Citations

dimensions_citation
133 Dimensions

Readers on

mendeley
192 Mendeley